IHT Wealth Management’s Heron Therapeutics HRTX Stock Holding History

IHT Wealth Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-12,025	Closed	-$129K	–	826
2021 Q3	$129K	Hold	12,025	–	–	0.01%	770
2021 Q2	$187K	Hold	12,025	–	–	0.01%	880
2021 Q1	$195K	Sell	12,025 -9,036	-43%	-$161K	0.01%	782
2020 Q4	$446K	Buy	21,061 +9,166	+77%	+$159K	0.04%	444
2020 Q3	$176K	Hold	11,895	–	–	0.02%	608
2020 Q2	$175K	Buy	+11,895	New	+$195K	0.02%	536
2017 Q4	–	Sell	-43	Closed	-$701	–	1728
2017 Q3	$1K	Buy	+43	New	+$675	﹤0.01%	1314

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

IHT Wealth Management's HRTX Position: Q4 2021 in Review

IHT Wealth Management sold out of Heron Therapeutics (HRTX) in Q4 2021, closing a stake of 12,025 shares — an estimated $129K sold.

IHT Wealth Management first reported a position in HRTX in Q3 2017 and held it in 7 quarters. The position peaked at $446K in Q4 2020. 200 funds tracked by Wall St. Rank hold HRTX as of Q4 2021.

IHT Wealth Management reported no remaining Heron Therapeutics position as of Q4 2021 after selling out during the quarter.
IHT Wealth Management sold 12,025 Heron Therapeutics shares in Q4 2021, an estimated $129K.
IHT Wealth Management first reported a position in Heron Therapeutics in Q3 2017 and held it in 7 quarters.
IHT Wealth Management's Heron Therapeutics position peaked at $446K in Q4 2020.
200 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2021.

Based on IHT Wealth Management's 13F filing for Q4 2021, filed 14 Feb 2022.